<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876876</url>
  </required_header>
  <id_info>
    <org_study_id>CK-LX3422</org_study_id>
    <nct_id>NCT00876876</nct_id>
  </id_info>
  <brief_title>International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia</brief_title>
  <official_title>International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioKine Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiokine Biopharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioKine Inc.</source>
  <brief_summary>
    <textblock>
      To demonstrate that after 12 weeks of open-label lixivaptan treatment, serum sodium is&#xD;
      maintained in hyponatremic patients continuing to receive lixivaptan compared to placebo&#xD;
      during the 4 week double blind treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Created Extension study - This study was no longer feasible&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate that after 12 weeks of open-label lixivaptan treatment, serum sodium is maintained in hyponatremic patients continuing to receive lixivaptan compared to placebo during the 4 week double blind treatment period.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To demonstrate that after 12 weeks of open-label lixivaptan treatment, improvements in the time to complete the Trail Making Test (Part B) will be maintained in patients continuing to receive lixivaptan.</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypervolemic Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Placebo QD or BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD or BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lixivaptan QD or BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lixivaptan QD or BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixivaptan</intervention_name>
    <description>Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.</description>
    <arm_group_label>Lixivaptan QD or BID</arm_group_label>
    <arm_group_label>Placebo QD or BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and Women with age greater than or equal to 18 years.&#xD;
&#xD;
          2. Prior successful participation in a randomized, blinded, placebo-controlled Phase 3&#xD;
             lixivaptan study of hyponatremia in Heart Failure (Protocol CK-LX3401) with evidence&#xD;
             of continued need for therapy as follows:&#xD;
&#xD;
               -  Patient completed full course of treatment (e.g., either placebo or lixivaptan).&#xD;
                  Treatment assignments for Protocol CK-LX3401 will not be unblinded prior to&#xD;
                  participation in the extension study.&#xD;
&#xD;
               -  Baseline serum sodium concentration &lt; 135 mEq/L following a 30 day post treatment&#xD;
                  follow-up period in a lixivaptan hyponatremia parent trial. Repeat measures of&#xD;
                  serum sodium are allowed; the last serum sodium result within 24 hours prior to&#xD;
                  randomization will serve as the qualifying measurement.&#xD;
&#xD;
          3. The patient has clinical evidence of volume overload with at least one of the&#xD;
             following:&#xD;
&#xD;
               -  Dyspnea&#xD;
&#xD;
               -  Pulmonary congestion (rales)&#xD;
&#xD;
               -  Peripheral edema&#xD;
&#xD;
               -  Increased jugular venous pressure and/or hepatic congestion with ascites&#xD;
&#xD;
               -  Chest x-ray consistent with CHF; OR&#xD;
&#xD;
               -  Plasma BNP ≥150 pg/mL or NT pro-BNP ≥ 450 pg/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant (positive pregnancy test), breastfeeding or who will not adhere&#xD;
             to the reproductive precautions as outlined in this protocol and in the informed&#xD;
             consent form.&#xD;
&#xD;
          2. Inability to provide informed consent.&#xD;
&#xD;
          3. Acute severe hyponatremia with overt symptoms of hyponatremia requiring immediate&#xD;
             medical intervention (e.g., coma, seizures).&#xD;
&#xD;
          4. Acute or transient hyponatremia (e.g., associated with head trauma or postoperative&#xD;
             state).&#xD;
&#xD;
          5. Hyponatremia in hypovolemic states. Hypovolemia is defined as the presence of clinical&#xD;
             evidence of fluid volume depletion.&#xD;
&#xD;
          6. Euvolemic Hyponatremia (e.g., SIADH, etc.). Euvolemic hyponatremia is defined as low&#xD;
             serum sodium in the presence of normal total body sodium due to mild to moderate&#xD;
             increases in total body water without edema.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <last_update_submitted>November 19, 2010</last_update_submitted>
  <last_update_submitted_qc>November 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Cesare Orlandi, MD</name_title>
    <organization>Cardiokine Biopharma, LLC</organization>
  </responsible_party>
  <keyword>hypervolemic hyponatremia</keyword>
  <keyword>serum sodium</keyword>
  <keyword>fluid overload</keyword>
  <keyword>heartfailure</keyword>
  <keyword>acute heart failure</keyword>
  <keyword>vasopressin antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

